{
    "clinical_study": {
        "@rank": "83999", 
        "arm_group": {
            "arm_group_label": "AdreView Arm 1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the reproducibility of quantitative measurements of\n      myocardial uptake of Iobenguane I 123 on planar and SPECT imaging following intravenous\n      (iv.) administration of AdreView.  Efficacy will be assessed based upon the absolute\n      differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days\n      apart."
        }, 
        "brief_title": "Open-label, Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView\u2122", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Failure (HF)", 
            "Ventricular Dysfunction, Left"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Ventricular Dysfunction, Left", 
                "Ventricular Dysfunction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject was originally diagnosed with NYHA Class II-III HF due to ischemic heart\n             disease at least 3 months or due to non-ischemic cardiomyopathy at least 6 months\n             before enrolment into the study.\n\n          -  The subject has Left Ventricular (LV) dysfunction with Left Ventricular Ejection\n             Fraction (LVEF) less than or equal to 35% measured by an appropriate method (e.g.,\n             radionuclide or contrast ventriculography, electrocardiogram (ECG)-gated SPECT\n             myocardial perfusion imaging [MPI], magnetic resonance imaging, CT or\n             echocardiography) within 6 months of enrolment into the study and documented in the\n             subject's medical record.\n\n          -  The subject has a history of compliance with prescribed HF medications and takes\n             Heart Failure (HF) guidelines-based medication at study entry including at a minimum\n             a beta-blocker and either an angiotensin converting enzyme inhibitor or angiotensin\n             receptor antagonist unless documented to be intolerant to any of these classes of\n             medications.\n\n          -  The subject has been on a stable medical regimen for a minimum of 3 months, with no\n             hospitalizations or change in HF medications or HF symptoms.\n\n          -  Subjects must be clinically stable for at least 7 days before enrolling in the study\n             (e.g., not experiencing continuing chest pain or hemodynamic instability).\n\n        Exclusion Criteria:\n\n          -  The subject has previously received 123I-mIBG or 131I-mIBG.\n\n          -  The subject has known or suspected hypersensitivity/allergy to iodine, Iobenguane or\n             to any of the excipients in AdreView.\n\n          -  The subject has had a heart transplant at any time prior to enrollment.\n\n          -  The subject had LVEF greater than 35% as measured by an appropriate method (e.g.,\n             radionuclide or contrast ventriculography, ECG-gated SPECT MPI, MR, CT, or\n             echocardiography) within 30 days prior to enrolment into the study.\n\n          -  The subject has received defibrillation (either external or via an implantable\n             cardioverter defibrillator [ICD]), anti-tachycardia pacing, or cardioversion to treat\n             an arrhythmic event in the previous 90 days.\n\n          -  The subject had a cardiac revascularization, insertion of an ICD, or acute myocardial\n             infarction within 30 days before study entry.\n\n          -  The subject has renal insufficiency (creatinine greater than 3 mg/dl)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936649", 
            "org_study_id": "GE-122-015"
        }, 
        "intervention": {
            "arm_group_label": "AdreView Arm 1", 
            "description": "AdreView 10 millicuries (mCi) as a single iv. administration", 
            "intervention_name": "AdreView", 
            "intervention_type": "Drug", 
            "other_name": "I-123 Iobenguane injection"
        }, 
        "intervention_browse": {
            "mesh_term": "3-Iodobenzylguanidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nuclear imaging", 
            "Radiopharmaceutical", 
            "Iobenguane", 
            "I-123", 
            "reproducibility", 
            "Quantitative measurements", 
            "myocardial uptake", 
            "SPECT imaging", 
            "planar imaging", 
            "AdreView\u2122"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "GE Healthcare"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView\u2122 (Iobenguane I 123 Injection)", 
        "overall_official": {
            "affiliation": "GE Healthcare", 
            "last_name": "Arnold Jacobson, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Test-retest reproducibility of Iobenguane I 123 myocardial uptake in heart failure (HF) subjects on planar imaging at 3 hours 50 minutes following intravenous (iv.) administration of AdreView.", 
            "measure": "Test-retest reproducibility of Iobenguane I 123 myocardial uptake in heart failure (HF) subjects on planar imaging", 
            "safety_issue": "No", 
            "time_frame": "Time zero equals the date of radiopharmaceutical imaging and up to 4 hours post administration of AdreView"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936649"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Test-retest reproducibility of Iobenguane I 123 myocardial uptake on single photon emission computed tomography (SPECT) imaging at 4 hours following intravenous administration of AdreView.", 
            "measure": "Test-retest reproducibility of Iobenguane I 123 myocardial uptake on single photon emission computed tomography (SPECT)", 
            "safety_issue": "No", 
            "time_frame": "Time zero equals the date of radiopharmaceutical imaging and up to 4 hours post administration of AdreView"
        }, 
        "source": "GE Healthcare", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "H2O Clinical LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Quintiles", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}